SCD Case Study
Sickle Cell Case Study
Supporting Therapy Commencement and Adherence in the Rare Disease Space with Private Patient Platforms, Patient Ambassadors, Social Media, and Content Strategy
Introduction
Sickle cell disease (SCD) affects approximately 100,000 people in the U.S., with 90% being non-Hispanic Black or African American and 3-9% being Hispanic or Latino. Due to its rarity and demographic impact, patients with SCD often face stigma and disbelief when seeking care, particularly when reporting painful vaso-occlusive crises (VOCs).
To improve patient acquisition and retention while educating individuals on the benefits of staying on infusion therapy, a pharmaceutical brand partnered with RxPx to develop a private patient platform. This initiative also included a multi-faceted strategy incorporating patient education, community engagement, and targeted support.
This case study examines the strategies and outcomes of a three-month campaign leveraging social tools,
influencers, and tailored educational content to support patients from diagnosis through ongoing treatment.
The Question
The Challenge
A pharmaceutical organization launched a new therapy to diminish instances and intensities of organ-damaging pain crises from a sickle cell disease diagnosis. As there is no cure for sickle cell disease, patients were reluctant to start and stay on infusion therapy.
Click to read the full case study and find out how RxPx
supported this major pharma brand with therapy adherence in
the rare disease space.
Results
%
ACQUISITION
66% increase in patient
app platform population
%
RETENTION
79% of users continued to return to
app platform once downloaded – 45% higher than the industry average
ENGAGEMENT
6000+ patients actively
engaged
“I used to sit in hospital beds and at home
wondering if there was someone out there
experiencing what I am experiencing and how
they’re getting through it. Now I KNOW!” – SCD Patient
